abstract |
The present invention relates to an anti-PAC1 monoclonal antibody capable of recognizing PAC1 having a native structure, a PAC1 activity modulator comprising the antibody (particularly an activity inhibitor), and a disease prevention / reduction associated with enhanced physiological activity of PAC1 comprising the antibody. A therapeutic agent, a diagnostic agent for a disease associated with abnormal PAC1 activity including the antibody, and a screening method for a substance that modulates PAC1 expression using the antibody and PAC1-expressing cells are provided. |